Janssen Biotech Inc.

02/09/2024 | Press release | Distributed by Public on 02/09/2024 08:10

Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and[...]